The firm’s CEO and chief investment manager is Alex Denner, who was previously the healthcare portfolio manager of Icahn Capital, headed by famous and ever-busy activist investor Carl Icahn.
At this point, Sarissa Capital Management’s strategy behind the Amarin investment is hard to gauge.
However, Vascepa remains hugely popular, even in the face of competition with generics.